| ￥3100 | |
| Z05869-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Biological Activity | Measured by its ability to inhibit trypsin cleavage of a fluorogenic peptide substrate, the IC50 value is < 0.75 nM. Test result meets the standard | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 32.1 kDa | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 40-50 kDa based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background | Oestrogens influence the pathophysiology and development of hormone-sensitive cancers, such as breast cancer. Tissue factor pathway inhibitor (TFPI) is a serine protease inhibitor of the extrinsic coagulation pathway and has recently been associated with breast cancer cell development. |
| Synonyms | LACI; TFPI1; EPI; TFI; convertin; TFPI |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
